Literature DB >> 28626849

Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Sikander Ailawadhi1, Kirtipal Bhatia2, Sonikpreet Aulakh2, Zahara Meghji2, Asher Chanan-Khan2.   

Abstract

Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.

Entities:  

Keywords:  Disparity; Myeloma; Outcomes

Mesh:

Year:  2017        PMID: 28626849     DOI: 10.1007/s11899-017-0393-y

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  46 in total

Review 1.  Racial and ethnic disparities in the receipt of cancer treatment.

Authors:  Vickie L Shavers; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

Review 2.  Myeloma in the Real World: What Is Really Happening?

Authors:  Krystal Bergin; Zoe McQuilten; Elizabeth Moore; Erica Wood; Andrew Spencer
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-12-26

3.  Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Authors:  Vishal Bhatnagar; Yin Wu; Olga G Goloubeva; Kathleen T Ruehle; Todd E Milliron; Carolynn G Harris; Aaron P Rapoport; Saul Yanovich; Edward A Sausville; Maria R Baer; Ashraf Z Badros
Journal:  Cancer       Date:  2014-12-02       Impact factor: 6.860

4.  Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.

Authors:  M R Modiano; P Villar-Werstler; J Crowley; S E Salmon
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

Review 5.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

6.  Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Authors:  Sara Bringhen; Maria Victoria Mateos; Sonja Zweegman; Alessandra Larocca; Antonietta Pia Falcone; Albert Oriol; Davide Rossi; Maide Cavalli; Pierre Wijermans; Roberto Ria; Massimo Offidani; Juan Jose Lahuerta; Anna Marina Liberati; Roberto Mina; Vincenzo Callea; Martijn Schaafsma; Chiara Cerrato; Roberto Marasca; Luca Franceschini; Andrea Evangelista; Ana-Isabel Teruel; Bronno van der Holt; Vittorio Montefusco; Giovannino Ciccone; Mario Boccadoro; Jesus San Miguel; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

7.  Impact of care at comprehensive cancer centers on outcome: Results from a population-based study.

Authors:  Julie A Wolfson; Can-Lan Sun; Laura P Wyatt; Arti Hurria; Smita Bhatia
Journal:  Cancer       Date:  2015-07-28       Impact factor: 6.860

8.  Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.

Authors:  Dianne Pulte; Maria Theresa Redaniel; Hermann Brenner; Lina Jansen; Mona Jeffreys
Journal:  Leuk Lymphoma       Date:  2013-09-03

Review 9.  Nuances in the Management of Older People With Multiple Myeloma.

Authors:  Charlotte Pawlyn; Francesca Gay; Alessandra Larocca; Vivek Roy; Sikander Ailawadhi
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

10.  Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT).

Authors:  Raegan W Durant; Jennifer A Wenzel; Isabel C Scarinci; Debora A Paterniti; Mona N Fouad; Thelma C Hurd; Michelle Y Martin
Journal:  Cancer       Date:  2014-04-01       Impact factor: 6.860

View more
  8 in total

1.  Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.

Authors:  Liang Chen; Ke Yi; Hongyan Lan; Yajun Zhang; Simin Jin; Xiaoyu Mou; Hongming Xian; Weijun Fu; Rong Li
Journal:  Ann Transl Med       Date:  2022-06

2.  Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Authors:  Sikander Ailawadhi; Susanna Jacobus; Rachael Sexton; Alexander K Stewart; Angela Dispenzieri; Mohamad A Hussein; Jeffrey A Zonder; John Crowley; Antje Hoering; Bart Barlogie; Robert Z Orlowski; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2018-07-06       Impact factor: 11.037

3.  Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.

Authors:  Sikander Ailawadhi; Sundar Jagannath; Hans C Lee; Mohit Narang; Robert M Rifkin; Howard R Terebelo; Brian G M Durie; Kathleen Toomey; James W Hardin; Cristina J Gasparetto; Lynne Wagner; James L Omel; Mia He; Lihua Yue; Elizabeth Dawn Flick; Amit Agarwal; Rafat Abonour
Journal:  Cancer       Date:  2020-07-24       Impact factor: 6.860

Review 4.  Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.

Authors:  Stergios Intzes; Marianthi Symeonidou; Konstantinos Zagoridis; Zoe Bezirgianidou; Georgios Vrachiolias; Athina Spanoudaki; Emmanouil Spanoudakis
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-01-01       Impact factor: 2.576

5.  Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations.

Authors:  Jiaxuan Xu; Peipei Xu; Qiaoyan Han; Jingjing Sun; Bing Chen; Xiaoqing Dong
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

6.  Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.

Authors:  Manav Gandhi; Viral Bakhai; Jash Trivedi; Adarsh Mishra; Fernando De Andrés; Adrián LLerena; Rohit Sharma; Sujit Nair
Journal:  Transl Oncol       Date:  2022-09-11       Impact factor: 4.803

Review 7.  Dissecting racial disparities in multiple myeloma.

Authors:  Catherine R Marinac; Irene M Ghobrial; Brenda M Birmann; Jenny Soiffer; Timothy R Rebbeck
Journal:  Blood Cancer J       Date:  2020-02-17       Impact factor: 11.037

8.  Education level as a predictor of survival in patients with multiple myeloma.

Authors:  Limei Xu; Xiuju Wang; Xueyi Pan; Xiaotao Wang; Qing Wang; Bingyi Wu; Jiahui Cai; Ying Zhao; Lijuan Chen; Wuping Li; Juan Li
Journal:  BMC Cancer       Date:  2020-08-08       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.